Because these T-cells play important roles in regulating human autoimmune diseases, we quantified T-cells populations expressing the NKR CD56, CD161 and CD94 in the peripheral blood of MS patients, in healthy control subjects (HS) and in patients with other neurological diseases (OND) [57] and showed that populations of CD161+ T-cells and CD94+ T-cells were significantly decreased in MS patients with primary progressive disease and secondarily progressive disease respectively whereas CD56+ T-cell numbers were unchanged. Here, KLRD1 is linked to myeloid sarcoma.